News Releases

Year

Jul 27, 2022

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Conference Call and Webcast Scheduled for Thursday, August 11, 2022 at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 27, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,

Jun 03, 2022

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) and options

May 18, 2022

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J. --(BUSINESS WIRE)--May 18, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C.

May 16, 2022

UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer

-- Multi-Center Retrospective Study was Presented at the 2022 American Urological Association Annual Meeting in New Orleans -- NEW ORLEANS --(BUSINESS WIRE)--May 16, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty

May 13, 2022

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

New data on in-office nephrostomy tube administration of JELMYTO® (mitomycin) for pyelocalyceal solution, the only non-surgical, kidney-sparing treatment for adults with low-grade upper tract urothelial cancer Results from the Phase 2b OPTIMA II trial of UGN-102 and impact of treatment in

May 10, 2022

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Jelmyto® net product revenue increased 81% over Q1 2021 to $13.6 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial is ongoing; completion of enrollment expected by end of 2022 Initiated novel, multi-arm Phase 1 clinical trial of UGN-301 in high-grade non-muscle invasive

May 03, 2022

UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Conference Call and Webcast Scheduled for Tuesday, May 10, 2022 at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today

Mar 29, 2022

UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

--Multi-arm Phase 1 study will evaluate the safety, tolerability and establish the recommended Phase 2 dose of monotherapy and combination therapy to treat recurrent non-muscle invasive bladder cancer (NMIBC) --Study design utilizes Master Protocol to accelerate evaluation of combination therapies

Mar 21, 2022

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

Jelmyto® net product revenue increased 42% over Q3 2021 with $16.2 million in Q4 2021; full-year net product revenue of $48.0 million in line with guidance Announced up to $100 million senior secured term loan facility with funds managed by Pharmakon Advisors , expected to support operations to

Mar 08, 2022

UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven

-- Initial Draw of $75 Million Available within 10 Business Days following Closing; Second Draw of $25 Million Available through the End of 2022 -- -- Reporting of Fourth Quarter and Full-Year Financial Results Rescheduled to March 21, 2022 -- PRINCETON, N.J. --(BUSINESS WIRE)--Mar.

Current page 1
Page 2
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on